<DOC>
	<DOCNO>NCT01520220</DOCNO>
	<brief_summary>The purpose study determine dose LY2784544 may safely administer participant myeloproliferative neoplasm .</brief_summary>
	<brief_title>Study LY2784544 Testing Alternative Dosing Participants With Myeloproliferative Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Have diagnosis polycythemia vera ( PV ) , essential thrombocythemia ( ET ) , myelofibrosis ( MF , primary secondary ) PV ET participant must fail intolerant standard therapy refuse take standard medication MF participant must meet least one follow criterion : Have intermediate1 , intermediate2 , highrisk MF accord Dynamic International Prognostic Scoring System ( DIPSS ) plus ; Have symptomatic MF spleen great 10 cm leave costal margin ; Have postpolycythemic MF ( postPV MF ) ; Have postessential thrombocythemic MF ( postET MF ) All participant must meet following criterion : Have give write informed consent prior studyspecific procedure Have adequate organ function , include : Hepatic : Direct bilirubin less equal 1.5 time upper limit normal ( ULN ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) less equal 2.5 time ULN Renal : Serum creatinine less equal 1.5 time ULN Bone Marrow Reserve : Absolute neutrophil count ( ANC ) ≥1000/mcL , platelet ≥25,000/mcL , platelet ≥50,000 PV ET participant . Have performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous approved therapy MF , include chemotherapy , immunomodulating therapy ( example , thalidomide , interferonalpha ) , immunosuppressive therapy ( example , corticosteroid &gt; 10 mg/day prednisone equivalent ) , radiotherapy , erythropoietin , thrombopoietin , granulocyte colonystimulating factor ( GSF ) least 14 day recover acute effect therapy . Hydroxyurea use control blood cell count permit study entry participant maintain stable dose least 4 week . Low dose acetylsalicylic acid ( aspirin ; 81 100 mg ) permit well Are reliable willing make available duration study willing follow study procedure Males female reproductive potential must agree use medically approve contraceptive precaution study 3 month follow last dose study drug Females childbearing potential must negative urine pregnancy test less equal 7 day first dose study drug must also breastfeed Are able swallow capsules/tablets For participant undergone recent major surgery , least 28 day must elapse surgery study participation , participant must achieve , opinion treat physician , least good recovery surgical procedure Potential participant may include study follow apply screen : Have receive treatment within 14 day initial dose study drug experimental agent receive regulatory approval indication Have QTc interval &gt; 470 millisecond ( msec ) use Bazett 's formula Have serious preexist medical condition , opinion investigator , would preclude participation study ( example , gastrointestinal ( GI ) disorder cause clinically significant symptom nausea , vomit , diarrhea , malabsorption syndrome ) Are currently treat agent metabolize cytochrome P450 ( CYP ) 3A4 narrow therapeutic margin ( example , alfentanil , cyclosporine , diergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus ) CYP2B6 ( example , cyclophosphamide , ifosfamide , tamoxifen , efavirenz , propofol , methadone , bupropion ) Have receive hematopoietic stem cell transplant Have second primary malignancy judgment investigator sponsor , may affect interpretation result Have active fungal , bacterial , and/or know viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) Have history congestive heart failure New York Heart Association ( NYHA ) Class great 2 ( NYHA Class 1 2 eligible ) , unstable angina , recent myocardial infarction ( within 6 month prior administration study drug ) , document history ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>